Workflow
健帆生物(300529) - 2025 Q3 - 季度财报
2025-10-29 09:15
Revenue and Profitability - Revenue for Q3 2025 was CNY 421,605,411.16, a decrease of 39.78% year-over-year, and year-to-date revenue was CNY 1,556,021,993.54, down 29.13% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2025 was CNY 63,507,610.17, a decline of 73.44% year-over-year, with year-to-date net profit at CNY 453,230,155.40, down 42.75%[4] - Basic earnings per share for Q3 2025 was CNY 0.083, a decrease of 72.33% compared to the same period last year, while diluted earnings per share was CNY 0.080, down 72.41%[4] - Total operating revenue for the current period is ¥1,556,021,993.54, a decrease of 29.1% compared to ¥2,195,690,243.92 in the previous period[25] - Net profit for the current period is ¥451,858,349.46, representing a decline of 42.7% from ¥788,826,841.30 in the previous period[26] - Basic earnings per share decreased to ¥0.59 from ¥0.99, a drop of 40.4%[26] Assets and Liabilities - Total assets as of September 30, 2025, were CNY 5,536,100,604.25, an increase of 2.84% from the end of the previous year[4] - The total current assets increased to ¥2,915,854,287.40 from ¥2,783,662,467.05, representing a growth of approximately 4.75%[22] - The total liabilities increased slightly from ¥2,048,784,541.14 to ¥2,107,445,959.36, reflecting a growth of about 2.00%[24] - The total equity attributable to shareholders rose from ¥3,333,906,225.54 to ¥3,429,268,141.05, an increase of approximately 2.87%[24] - The company's short-term borrowings decreased from ¥77,505,234.56 to ¥58,422,405.98, a reduction of about 24.65%[24] - The non-current liabilities increased from ¥1,281,991,218.31 to ¥1,422,240,153.75, representing a growth of about 10.95%[24] Cash Flow - Cash flow from operating activities year-to-date was CNY 573,240,155.17, a decrease of 34.23% compared to the same period last year[4] - Net cash flow from operating activities is ¥573,240,155.17, down 34.2% from ¥871,604,805.56 in the previous period[27] - Cash received from other operating activities increased by 69.88% to ¥96,557,078.25, mainly due to an increase in government subsidies related to assets[14] - Cash paid for other operating activities decreased by 34.12% to ¥265,858,918.17, attributed to cost control measures[14] - Cash received from investment income dropped by 64.20% to ¥8,757,199.60, mainly due to a decrease in maturing financial products[14] - Cash received from financing activities surged by 799.93% to ¥449,965,192.89, primarily due to the redemption of financial products related to financing activities[14] - Cash paid for debt repayment decreased by 91.18% to ¥32,120,327.44, reflecting a reduction in bank loan repayments[14] Financial Performance and Changes - The company reported a significant increase in trading financial assets, which rose by 241.90% to CNY 2,027,709,429.35 due to the purchase of wealth management products[8] - The company’s financial expenses increased by 33.65% to CNY 30,737,763.62, primarily due to adjustments in the funding structure and a decrease in deposit interest income[12] - The company experienced a 63.61% decline in other income, totaling CNY 18,950,231.78, mainly due to reduced government subsidies and VAT refunds[12] - The company reported a significant increase in fair value changes, with a gain of CNY 30,921,869.97, reflecting a 9137.44% increase due to changes in the fair value of held financial products[12] - Tax refunds received decreased by 33.63% to ¥946,942.18 compared to the previous year, primarily due to a reduction in VAT refunds[14] Market and Growth Opportunities - The number of hemodialysis patients in China is expected to grow by 12% year-on-year, reaching approximately 1.027 million by the end of 2024[15] - The introduction of new medical service pricing guidelines in June 2025 will include independent pricing for "hemodialysis perfusion" and "plasma adsorption," indicating a policy-driven growth opportunity[15] - The company is actively expanding into international markets and increasing new product development in metabolic cardiovascular diseases and related health management[16] Shareholder Information - The total number of common shareholders at the end of the reporting period was 51,243[18] Accounting and Audit - The company has not undergone an audit for the third quarter financial report[29] - The company plans to implement new accounting standards starting from 2025[29]
太平洋(601099) - 2025 Q3 - 季度财报
2025-10-29 09:15
Financial Performance - The company's operating revenue for Q3 2025 reached ¥421,832,609.43, representing a year-over-year increase of 30.45%[3] - Total profit for the quarter was ¥170,461,695.86, up 89.02% compared to the same period last year[3] - Net profit attributable to shareholders was ¥124,912,461.06, reflecting an 83.89% increase year-over-year[3] - The net profit after deducting non-recurring gains and losses was ¥123,589,954.26, which is an increase of 85.56% from the previous year[3] - The basic earnings per share for the quarter was ¥0.018, an increase of 80.00% compared to the same period last year[3] - Total operating revenue for the first three quarters of 2025 reached ¥1,036,614,562.56, a 19.9% increase compared to ¥864,742,464.13 in the same period of 2024[19] - Net profit for the first three quarters of 2025 was ¥245,533,643.04, up 80.1% from ¥136,251,511.92 in the first three quarters of 2024[20] - Basic and diluted earnings per share for the first three quarters of 2025 were both ¥0.036, compared to ¥0.020 in the same period of 2024[21] - The company reported a total comprehensive income of ¥245,123,692.79 for the first three quarters of 2025, compared to ¥135,680,156.42 in 2024, reflecting a significant increase[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥20,002,004,857.61, an increase of 8.58% from the end of the previous year[3] - As of September 30, 2025, total assets reached CNY 20,002,004,857.61, an increase from CNY 18,421,363,692.69 as of December 31, 2024, representing a growth of approximately 8.6%[14] - Total liabilities were CNY 10,057,612,982.02, up from CNY 8,721,893,935.35, which is an increase of about 15.3%[15] - The company's equity attributable to shareholders rose to CNY 9,945,279,402.69 from CNY 9,700,261,958.94, showing an increase of approximately 2.5%[16] - The company's total equity (including minority interests) was CNY 9,944,391,875.59, compared to CNY 9,699,469,757.34, reflecting a growth of about 2.5%[16] Cash Flow and Liquidity - Cash and cash equivalents amounted to CNY 7,436,622,373.68, up from CNY 6,837,235,092.75, indicating an increase of about 8.8%[14] - The net cash flow from operating activities was ¥400,612,617.81, down 70.4% from ¥1,353,875,172.63 in the previous year[23] - Cash and cash equivalents at the end of the period amounted to ¥9,389,447,136.84, an increase from ¥8,072,725,811.58 at the end of the same period in 2024[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 365,169[10] - The company has pledged 580,810,000 shares to Huachuang Securities, with a total of 744,039,975 shares frozen and subject to judicial auction[12] Risk and Coverage Ratios - The risk coverage ratio decreased to 484.42% from 514.79% at the end of the previous year[6] - The liquidity coverage ratio significantly decreased to 813.68% from 1,963.29% at the end of the previous year[6] Income Sources - Net interest income increased to ¥193,953,386.53, compared to ¥186,270,435.47 in the previous year, reflecting a growth of 3.6%[19] - The net income from commission and fee-based services rose to ¥497,626,653.72, a 10.9% increase from ¥448,639,581.59 in 2024[19] - Investment income surged to ¥305,251,471.72, significantly higher than ¥143,957,675.90 in the same period last year, marking a growth of 112.5%[19] Operating Expenses - Operating expenses totaled ¥698,499,427.20, a slight increase of 3.6% from ¥676,855,628.76 in 2024[20]
奥精医疗(688613) - 2025 Q3 - 季度财报
2025-10-29 09:15
Financial Performance - The company's operating revenue for the third quarter reached ¥56,021,033.87, an increase of 16.54% compared to the same period last year[4] - Total profit for the quarter was ¥5,208,841.85, reflecting a significant increase of 294.96% year-over-year[4] - Net profit attributable to shareholders was ¥5,965,270.89, up 237.64% from the previous year[4] - Basic earnings per share for the quarter were ¥0.04, representing a 233.33% increase compared to the same period last year[5] - Total operating revenue for the first three quarters of 2025 reached ¥156,057,979.41, an increase of 5.8% compared to ¥148,311,250.58 in the same period of 2024[21] - Net profit for the first three quarters of 2025 was ¥10,595,768.44, a significant recovery from a net loss of ¥810,499.78 in the same period of 2024[22] - Earnings per share for the first three quarters of 2025 were ¥0.10, compared to ¥0.04 in the same period of 2024, indicating a 150% increase[23] - The total comprehensive income for the first three quarters of 2025 was ¥11,365,996.85, a recovery from a loss of ¥785,374.73 in the same period of 2024[23] Cash Flow - The cash flow from operating activities showed a negative net amount of ¥258,934.31, a deterioration of 97.68% compared to the same period last year[4] - Operating cash inflow totaled $199.65 million, up from $131.79 million year-over-year[27] - Cash outflow from operating activities was $204.15 million, compared to $152.38 million in the previous year[27] - Net cash flow from operating activities was -$4.50 million, an improvement from -$20.59 million year-over-year[27] - Cash inflow from investment activities was $25.04 million, down from $985.28 million in the previous year[27] - Cash outflow from investment activities totaled $47.97 million, compared to $974.45 million last year[27] - Net cash flow from investment activities was -$22.93 million, a decline from $10.83 million year-over-year[27] - Cash inflow from financing activities was $14.71 million, down from $23.54 million in the previous year[29] - Cash outflow from financing activities was $6.46 million, compared to $15.05 million last year[29] - Net cash flow from financing activities was $8.24 million, slightly down from $8.49 million year-over-year[29] - The ending cash and cash equivalents balance was $137.94 million, down from $159.99 million at the end of the previous year[29] Assets and Liabilities - The total assets of the company at the end of the reporting period were ¥1,544,836,085.14, a slight increase of 0.37% from the end of the previous year[5] - The total current assets as of September 30, 2025, amounted to RMB 1,215,045,444.13, showing an increase from RMB 1,196,396,879.83 as of December 31, 2024, representing a growth of approximately 1.5%[17] - Total liabilities decreased to ¥96,058,675.71 in 2025 from ¥119,200,213.96 in 2024, showing a reduction of approximately 19.4%[20] - Owner's equity attributable to shareholders increased to ¥1,435,033,515.43 in 2025 from ¥1,402,874,383.57 in 2024, reflecting a growth of 2.3%[20] - Total assets reached RMB 1,544,836,085.14, slightly up from RMB 1,539,163,337.61, showing a marginal increase of approximately 0.4%[18] Research and Development - Research and development expenses totaled ¥11,722,614.67, accounting for 20.93% of operating revenue, an increase of 4.69 percentage points year-over-year[5] - Research and development expenses for the first three quarters of 2025 were ¥27,453,429.72, compared to ¥24,366,528.85 in 2024, marking an increase of 12.8%[21] Shareholder Information - The company reported a total of 9,862 common shareholders at the end of the reporting period[12] - The top shareholder, HU ERIC GANG, holds 9,487,066 shares, representing 6.92% of the total shares[12] Operational Issues - The company has not reported any significant changes in shareholder relationships or financing activities during the reporting period[14] - There are no applicable audit opinions for the financial statements as they are unaudited[15] - The company has not identified any other significant operational issues during the reporting period[15] Other Income - The company reported a significant increase in other income, totaling ¥2,853,312.23 in 2025 compared to ¥293,569.96 in 2024[22] Inventory and Receivables - Accounts receivable decreased to RMB 57,562,253.96 from RMB 67,159,276.75, a decline of about 14%[17] - Inventory increased significantly to RMB 85,598,891.55 from RMB 54,577,004.67, representing an increase of approximately 56.9%[18]
吉林高速(601518) - 2025 Q3 - 季度财报
2025-10-29 09:15
Financial Performance - Total operating revenue for Q3 2025 reached ¥356,805,612.58, an increase of 8.24% compared to the same period last year[4] - Total profit for the period was ¥237,724,949.18, reflecting a growth of 10.18% year-over-year[4] - Net profit attributable to shareholders was ¥167,660,138.25, up 15.14% from the previous year[4] - The net profit after deducting non-recurring gains and losses was ¥167,317,799.19, representing a 16.48% increase year-over-year[4] - Total operating revenue for the first three quarters of 2025 reached ¥906,167,795.89, an increase of 4.9% compared to ¥869,024,201.65 in the same period of 2024[15] - Operating profit for the first three quarters of 2025 was ¥561,513,656.06, slightly higher than ¥553,753,140.80 in 2024, indicating a growth of 1.4%[15] - The net profit for the first three quarters of 2025 is CNY 430,013,825.24, an increase from CNY 423,853,661.31 in the same period of 2024, representing a growth of approximately 1.4%[16] - The total comprehensive income for the first three quarters of 2025 is CNY 430,013,825.24, compared to CNY 423,853,661.31 in 2024, indicating a year-over-year increase of about 1.4%[16] Assets and Liabilities - Total assets as of September 30, 2025, amounted to ¥6,502,649,909.05, an increase of 3.52% from the end of the previous year[5] - Total current assets as of September 30, 2025, amounted to ¥2,347,939,662.87, compared to ¥1,955,218,826.65 at the end of 2024, representing an increase of 20%[12] - Total assets reached ¥6,502,649,909.05 as of September 30, 2025, compared to ¥6,281,374,586.10 at the end of 2024, marking a growth of 3.5%[13] - Total liabilities decreased to ¥414,269,037.27 as of September 30, 2025, down from ¥460,419,964.78 at the end of 2024, a reduction of 10%[13] Shareholder Information - Shareholder equity attributable to the parent company was ¥5,619,520,477.43, up 4.33% from the previous year[5] - The number of ordinary shareholders at the end of the reporting period was 41,203[9] - The largest shareholder, Jilin Provincial Expressway Group Co., Ltd., holds 54.35% of the shares[9] Cash Flow and Expenses - The company's cash and cash equivalents increased to ¥2,011,535,138.29 as of September 30, 2025, compared to ¥1,670,361,842.38 at the end of 2024, reflecting a growth of 20.4%[12] - The operating cash flow for the first three quarters of 2025 is CNY 519,095,483.53, up from CNY 495,038,951.78 in 2024, reflecting an increase of approximately 4.1%[19] - The cash and cash equivalents at the end of the third quarter of 2025 amount to CNY 2,004,495,325.79, compared to CNY 1,806,344,022.07 at the end of the same period in 2024, showing a growth of about 11%[20] - The company reported a decrease in cash inflow from operating activities, totaling CNY 936,991,659.13 in 2025, down from CNY 949,738,086.33 in 2024, which is a decline of approximately 1.3%[19] - The cash outflow from investing activities for the first three quarters of 2025 is CNY 9,523,607.36, a decrease from CNY 10,547,345.61 in 2024, indicating a reduction of about 9.7%[20] - The net cash flow from financing activities in 2025 is CNY -162,554,670.54, compared to CNY -176,960,996.50 in 2024, showing an improvement of approximately 8.1%[20] Expenses - The company reported a decrease in management expenses to ¥47,734,457.74 in the first three quarters of 2025, down from ¥51,088,797.60 in 2024, a decline of 6.9%[15] - Research and development expenses increased to ¥2,807,487.13 in the first three quarters of 2025, compared to ¥2,493,305.38 in 2024, reflecting a growth of 12.6%[15] Other Information - The weighted average return on equity for the period was 3.01%, a decrease of 4.17 percentage points compared to the previous year[5] - The company received government subsidies amounting to ¥276,424.68 during the period, contributing to its non-recurring gains[7] - The basic and diluted earnings per share remain stable at CNY 0.21 for both 2025 and 2024[16] - The company has not reported any net profit from subsidiaries prior to consolidation for both periods[16] - The company is not applying new accounting standards for the year 2025[21]
三鑫医疗(300453) - 2025 Q3 - 季度财报
2025-10-29 09:15
Financial Performance - The company's operating revenue for Q3 2025 reached ¥406,794,256.65, representing a 2.76% increase year-over-year[4] - Net profit attributable to shareholders was ¥69,861,041.47, up 13.29% compared to the same period last year[4] - The basic earnings per share increased by 15.08% to ¥0.1366 for the current period[4] - Total operating revenue for the current period reached ¥1,167,602,224.43, an increase of 7.4% compared to ¥1,082,325,012.30 in the previous period[21] - Net profit for the current period was ¥204,312,790.12, representing a growth of 11.4% from ¥183,343,938.37 in the previous period[22] - Basic earnings per share increased to ¥0.3573 from ¥0.3232, marking a rise of 10.6%[23] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥2,310,054,116.09, reflecting a 3.93% increase from the end of the previous year[4] - Total assets reached ¥2,310,054,116.09, compared to ¥2,222,709,961.44, indicating a growth of 3.9%[19] - Total liabilities increased to ¥834,279,303.35 from ¥814,055,748.31, reflecting a rise of 2.7%[19] - Non-current assets totaled ¥1,480,068,112.76, up from ¥1,398,754,616.01, showing an increase of 5.8%[19] - Current liabilities decreased slightly to ¥558,402,423.00 from ¥577,595,822.70, a decline of 3.4%[19] Cash Flow - Operating cash inflow for the current period reached ¥1,354,172,234.70, an increase of 11.6% compared to ¥1,212,962,998.57 in the previous period[24] - Net cash flow from operating activities was ¥325,422,401.90, slightly up from ¥323,591,496.43 in the previous period[24] - Cash inflow from investment activities totaled ¥488,203,748.46, significantly higher than ¥154,621,615.16 in the previous period[25] - Net cash flow from investment activities was -¥272,215,709.56, worsening from -¥224,909,519.62 in the previous period[25] - Cash inflow from financing activities was ¥81,840,000.00, down from ¥168,434,775.00 in the previous period[25] - Net cash flow from financing activities was -¥199,338,269.68, compared to -¥186,197,100.44 in the previous period[25] - The ending balance of cash and cash equivalents was ¥135,355,790.28, up from ¥111,439,210.26 in the previous period[25] Investments - The company reported a significant increase in investment income of 1339.59%, totaling ¥3,513,977.61, primarily due to increased financial management returns[8] - The company reported an investment income of ¥3,513,977.61, recovering from a loss of ¥283,479.34 in the previous period[22] - The company received ¥479,831,813.95 from investment recoveries, a substantial increase from ¥152,241,110.00 in the previous period[25] - The company paid ¥570,471,075.00 for investments, significantly higher than ¥223,000,000.00 in the previous period[25] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 23,101[11] - The largest shareholder, Peng Yixing, holds 32,231,511 shares, representing a significant portion of the company's equity[12] - The company has a total of 165,183,790 shares subject to lock-up agreements, with 2,831,750 shares released during the period[15] - The company has a total of 96,694,533 shares under lock-up for Peng Yixing, which will remain locked for 75% of the term[14] - The company has not reported any changes in the status of its major shareholders participating in margin trading activities[12] Other Financial Metrics - The company’s weighted average return on equity was 5.15%, an increase of 0.41% from the previous year[4] - The company received government subsidies amounting to ¥20,147,396.69, a 73.66% increase compared to the previous year[8] - Research and development expenses for the current period were ¥50,894,409.75, compared to ¥44,733,074.43, an increase of 13.4%[21] - Cash and cash equivalents decreased by 48.67% to ¥148,770,600.97, mainly due to increased purchases of financial products[9] - The company reported a decrease in cash and cash equivalents, with a balance of ¥148,770,600.97 compared to ¥289,846,781.19 at the beginning of the period, reflecting a decline of approximately 48.7%[17] - Trading financial assets increased significantly to ¥321,713,269.90 from ¥178,481,242.87, marking an increase of about 80.0%[17] - Inventory levels rose to ¥215,956,705.08 from ¥195,673,582.44, indicating an increase of approximately 10.4%[17] - Accounts receivable slightly decreased to ¥81,576,277.11 from ¥83,256,881.36, a decline of about 2.0%[17] - The company’s total current assets include various components, with a notable increase in prepayments to ¥15,806,640.89 from ¥13,223,949.61, an increase of about 19.5%[17] - The company’s total receivables financing increased to ¥7,373,398.77 from ¥2,770,415.37, reflecting a growth of approximately 165.5%[17]
恒兴新材(603276) - 2025 Q3 - 季度财报
2025-10-29 09:15
江苏恒兴新材料科技股份有限公司 2025 年第三季度报告 证券代码:603276 证券简称:恒兴新材 江苏恒兴新材料科技股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整,不存在虚假记载、误 导性陈述或重大遗漏,并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 (一) 主要会计数据和财务指标 单位:元 币种:人民币 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 214,019,294.48 | 2.87 | 606 ...
博瑞传播(600880) - 2025 Q3 - 季度财报
2025-10-29 09:15
Financial Performance - The company's operating revenue for the third quarter was CNY 119,946,187, representing a year-on-year increase of 10.65%[3] - The net profit attributable to shareholders was a loss of CNY 1,328,278.14, a decrease of 136.67% compared to the same period last year[3] - The total revenue for the year-to-date period reached CNY 404,876,871.92, reflecting a growth of 43.71%[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of CNY 1,328,780.33, down 137.74% year-on-year[3] - The total profit for the year-to-date period was CNY 15,303,652.78, a decrease of 31.67% compared to the same period last year[3] - The company reported a total operating income of CNY 130,038,499.89 for the third quarter, which is a 9.86% increase year-on-year[3] - Total operating revenue for the first three quarters of 2025 reached CNY 434,835,214.94, a significant increase from CNY 308,706,377.92 in the same period of 2024, representing an increase of approximately 40.8%[15] - Operating income for the first three quarters of 2025 was CNY 404,876,871.92, compared to CNY 281,738,869.98 in 2024, reflecting a growth of about 43.6%[15] - The company's net profit for the first three quarters of 2025 was CNY 356,878.30, a decrease from CNY 11,006,085.16 in the same period of 2024, showing a decline of about 96.8%[16] Assets and Liabilities - The total assets at the end of the reporting period were CNY 4,135,392,108.90, an increase of 0.54% compared to the end of the previous year[4] - The total assets of the company as of the reporting date were CNY 4,135,392,108.90, slightly up from CNY 4,113,379,378.10 in the previous period[14] - Total liabilities increased to CNY 871,204,316.99 from CNY 852,135,437.64, reflecting a rise of approximately 2.5%[14] - The company's equity attributable to shareholders was CNY 3,039,345,228.17, a slight decrease from CNY 3,040,091,886.49[14] Cash Flow - The cash flow from operating activities showed a net outflow of CNY 143,571,688.41, down 38.44% year-on-year[3] - Cash inflow from operating activities for the first nine months reached $513.52 million, up from $329.59 million in the same period last year, representing a 55.7% increase[21] - Net cash outflow from operating activities was $143.57 million, compared to $103.71 million in the previous year, indicating a worsening of 38.5%[21] - Investment activities generated a net cash inflow of $64.01 million, a significant recovery from a net outflow of $9.52 million in the same period last year[22] - Total cash inflow from financing activities was $197.00 million, compared to $127.04 million in the previous year, marking a 55% increase[22] - Net cash outflow from financing activities was $61.53 million, a decrease from $70.34 million in the same period last year, showing an improvement of 12.2%[22] - The ending cash and cash equivalents balance was $457.92 million, up from $423.45 million at the end of the previous year, reflecting a 8.1% increase[22] Shareholder Information - Total number of common shareholders at the end of the reporting period is 54,341[9] - The largest shareholder, Chengdu Borui Investment Holding Group Co., Ltd., holds 255,519,676 shares, accounting for 23.37% of total shares[9] - The second largest shareholder, Chengdu Media Group, holds 133,612,937 shares, representing 12.22% of total shares[9] - The company has no significant changes in the top ten shareholders or their shareholding status due to securities lending[10] Operational Insights - Non-recurring gains and losses for the period amounted to CNY 502.19, significantly lower than the previous year's CNY 7,407,194.47[6] - Research and development expenses for the first three quarters of 2025 were CNY 22,688,515.00, down from CNY 34,612,484.72 in 2024, indicating a reduction of about 34.5%[16] - The company reported a financial expense of CNY 3,025,302.75, significantly higher than CNY 113,016.24 in the previous year, marking an increase of approximately 2,580.5%[16] - There are no other significant reminders regarding the company's operational status during the reporting period[11] Current Assets - Total current assets as of September 30, 2025, amount to ¥1,206,056,246.74, a decrease from ¥1,233,442,346.88 as of December 31, 2024[12] - Cash and cash equivalents are reported at ¥488,047,781.12, down from ¥510,917,087.26[12] - Accounts receivable increased to ¥397,581,112.84 from ¥316,252,197.72, indicating a growth of approximately 25.7%[12] - Inventory decreased to ¥62,532,321.71 from ¥69,419,276.35, a decline of about 9.3%[12] - Long-term equity investments rose to ¥487,995,552.38 from ¥479,824,240.29, reflecting an increase of approximately 1.5%[12]
博杰股份(002975) - 2025 Q3 - 季度财报
2025-10-29 08:55
珠海博杰电子股份有限公司 2025 年第三季度报告 证券代码:002975 证券简称:博杰股份 公告编号:2025-113 珠海博杰电子股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整,不存在虚假记载、误导性陈述或重 大遗漏,并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明:保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 1 | 项目 | 本报告期金额 | 年初至报告期期末金额 | 说明 | | --- | --- | --- | --- | | 非流动性资产处置损益(包括已计提资产减 | | | 主要系出售焜原光电部分股权 | | | 44,890,670.68 | 44,714,663.45 | 和焜原光电转其他权益工具投 | | 值准备的冲销部分) | | | 资核算的收益。 | | 计入当期损益的政府补助(与公司正常经营 | | ...
凯淳股份(301001) - 2025 Q3 - 季度财报
2025-10-29 08:50
本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 上海凯淳实业股份有限公司 2025 年第三季度报告 证券代码:301001 证券简称:凯淳股份 公告编号:2025-049 上海凯淳实业股份有限公司 2025 年第三季度报告 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整,不存在虚假记载、误导性陈述或重 大遗漏,并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明:保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 1 上海凯淳实业股份有限公司 2025 年第三季度报告 一、主要财务数据 (一) 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入(元) | 66,867,016.05 | -25.46% ...
昊志机电(300503) - 2025 Q3 - 季度财报
2025-10-29 08:50
广州市昊志机电股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整,不存在虚假记载、误导性陈述或重 大遗漏,并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明:保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 广州市昊志机电股份有限公司 2025 年第三季度报告 证券代码:300503 证券简称:昊志机电 公告编号:2025-078 1 广州市昊志机电股份有限公司 2025 年第三季度报告 一、主要财务数据 (一) 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入(元) | 439,977,367.63 | 24. ...